Table 2.
Characteristics of patients who exhibited vaccine-related side effects.
| Variable | Side effect (N = 20) | Test of significance | P value |
|---|---|---|---|
| Age | T = −2.05 | 0.045 | |
| Mean ± SD | 14.55 ± 1.50 | ||
| Median (min ∼ max) | 15 (12–17) | ||
| Gender | X2 = 1.594 | 0.207 | |
| Male | 12 (60%) | ||
| Female | 8 (40%) | ||
| Children education | X2 = 10.743 | 0.010 | |
| junior high school | 10 (50%) | ||
| senior high school | 9 (45%) | ||
| undergraduate | 1 (5%) | ||
| The form of seizure | X2 = 0.703 | 0.945 | |
| Generalized seizures | 3 (15%) | ||
| Focal seizures | 3 (15%) | ||
| Generalized-focal seizures | 12 (60%) | ||
| Unknown | 2 (10%) | ||
| The time child was diagnosed with epilepsy (Months) | T = 0.900 | 0.371 | |
| Mean ± SD | 79.8 ± 34.882 | ||
| Median (min ∼ max) （Months) | 90 (0–132) | ||
| The vaccine type | X2 = 27.156 | <0.001 | |
| Sinopharm (Beijing): BBIBP-CorV (Vero Cells) two doses | 15 (75%) | ||
| CanSino: Ad5-nCoV two doses | 5 (25%) | ||
| Seizure frequency | X2 = 13.274 | 0.004 | |
| None | 4 (20%) | ||
| low frequency | 15 (75%) | ||
| high frequency | 1 (5%) | ||